8-KMaterial AgreementsFinancial Events

VERTEX PHARMACEUTICALS INC / MA 8-K Report, Material Agreement (Sep 21, 2020)

Filed September 21, 2020For Securities:VRTX

Summary

Vertex Pharmaceuticals Incorporated (VRTX) has entered into a significant Credit Agreement that establishes a $2.0 billion senior unsecured revolving facility, with an option to increase this capacity by an additional $500 million. This new facility, maturing on September 18, 2022, provides the company with substantial financial flexibility for general corporate purposes. The terms include variable interest rates based on either a base rate or Eurocurrency rate, plus an applicable margin that is tied to Vertex's consolidated leverage ratio, indicating a cost of borrowing that can fluctuate with the company's financial health. The Credit Agreement also incorporates important covenants for investors to note, including financial requirements to maintain a consolidated leverage ratio of 3.50 to 1.00 (or 4.00 to 1.00 post-material acquisition) and a consolidated interest coverage ratio of 2.50 to 1.00. These covenants demonstrate the company's commitment to financial discipline and underscore potential triggers for lender actions should these ratios be breached. The agreement is secured by guarantees from certain domestic subsidiaries, subject to exceptions, and includes standard provisions for representations, warranties, and events of default.

Key Highlights

  • 1Entered into a $2.0 billion senior unsecured revolving credit facility, with an accordion feature to increase by an additional $500 million.
  • 2The credit facility matures on September 18, 2022, providing a medium-term source of funding.
  • 3Proceeds are designated for general corporate purposes, offering flexibility in capital allocation.
  • 4Interest rates are variable, tied to either a base rate or Eurocurrency rate, plus an applicable margin based on the company's leverage ratio.
  • 5Key financial covenants include maintaining a consolidated leverage ratio of 3.50:1.00 (extendable to 4.00:1.00 post-acquisition) and an interest coverage ratio of 2.50:1.00.
  • 6Certain domestic subsidiaries will provide guarantees for the facility, subject to exceptions.
  • 7The agreement includes standard representations, warranties, covenants, and events of default, allowing for remedies like loan acceleration upon default.

Frequently Asked Questions

The Credit Agreement provides Vertex Pharmaceuticals with a substantial $2.0 billion senior unsecured revolving credit facility, with an option to increase it by an additional $500 million. The funds are intended for general corporate purposes, which offers the company significant financial flexibility for operations, investments, or other strategic initiatives.

Investors should monitor Vertex's consolidated leverage ratio and consolidated interest coverage ratio. The Credit Agreement requires the company to maintain a leverage ratio of 3.50 to 1.00 (which can increase to 4.00 to 1.00 after a material acquisition) and an interest coverage ratio of 2.50 to 1.00. Breaching these covenants could lead to default and potential acceleration of the debt.

The loans under the Credit Agreement will bear interest at either a base rate or a Eurocurrency rate, plus an applicable margin. This margin varies from 0.500% to 0.875% for base rate loans and 1.500% to 1.875% for Eurocurrency loans, depending on Vertex's consolidated leverage ratio. This structure means the cost of borrowing is directly linked to the company's financial leverage, making it important for investors to track both the company's debt levels and its earnings.

The Credit Agreement matures on September 18, 2022. Loans under the facility can be prepaid at par without premium or penalty, and commitments can be reduced at any time, though standard LIBOR breakage costs may apply.